{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:55:19Z","timestamp":1787586919313,"version":"build-2736575974"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing lipoprotein (a)-related cardiovascular risk. Here, we describe the findings from key preclinical safety studies. In vitro, SLN360 specifically reduced LPA expression in primary human hepatocytes with no relevant off-target effects. In rats, 10\u2009mg\/kg subcutaneous SLN360 was distributed specifically to the liver and kidney (peak 126 or 246\u2009mg\/g tissue at 6\u2009h, respectively), with &amp;lt;1% of peak liver levels observed in all other tested organs. In vitro, no genotoxicity and no effect on human Ether-a-go-go Related Gene currents or proinflammatory cytokine production was observed, whereas in vivo, no SLN360-specific antibodies were detected in rabbit serum. In rat and nonhuman primate 29-day toxicology studies, SLN360 was well tolerated at all doses. In both species, known GalNAc-conjugated siRNA-induced microscopic changes were observed in the kidney and liver, with small increases in alanine aminotransferase and alkaline phosphatase observed in the high dose rats. Findings were in line with previously described siRNA-GalNAc platform-related effects and all observations were reversible and considered nonadverse. In cynomolgus monkeys, liver LPA messenger RNA and serum lipoprotein (a) were significantly reduced at day 30 and after an 8-week recovery period. No dose-related changes in safety assessment endpoints were noted. No SLN360-induced cytokine production, complement activation, or micronucleus formation was observed in vivo. The toxicological profile of SLN360 presented here is restricted to known GalNAc siRNA effects and no other toxicity associated with SLN360 has been noted. The preclinical profile of SLN360 confirmed suitability for entry into clinical studies.<\/jats:p>","DOI":"10.1093\/toxsci\/kfac067","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T15:35:46Z","timestamp":1655998546000},"page":"237-249","source":"Crossref","is-referenced-by-count":14,"title":["Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1972-2524","authenticated-orcid":false,"given":"David","family":"Rider","sequence":"first","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Chivers","sequence":"additional","affiliation":[{"name":"Integrated Biologix , Basel CH-4051, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Aretz","sequence":"additional","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Eisermann","sequence":"additional","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"L\u00f6ffler","sequence":"additional","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hauptmann","sequence":"additional","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Morrison","sequence":"additional","affiliation":[{"name":"Silence Therapeutics GmbH , Berlin 13125, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Campion","sequence":"additional","affiliation":[{"name":"Silence Therapeutics PLC , London W14 8TH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"2022092808034737400_kfac067-B1","author":"ASGR1 Expression Profile","year":"2021"},{"key":"2022092808034737400_kfac067-B2","author":"ASGR2 Expression Profile","year":"2021"},{"key":"2022092808034737400_kfac067-B3","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"2022092808034737400_kfac067-B4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2019.06.012","article-title":"High-throughput analysis reveals rules for target RNA binding and cleavage by AGO2","volume":"75","author":"Becker","year":"2019","journal-title":"Mol. Cell"},{"key":"2022092808034737400_kfac067-B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man - the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol. Microbiol. Scand"},{"key":"2022092808034737400_kfac067-B6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/nat.2015.0534","article-title":"OSWG recommendations for genotoxicity testing of novel oligonucleotide-based therapeutics","volume":"26","author":"Berman","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"2022092808034737400_kfac067-B7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1089\/nat.2013.0477","article-title":"Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics","volume":"24","author":"Berman","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"2022092808034737400_kfac067-B8","author":"BLAST search performed on NM_005577.4 Homo sapiens lipoprotein(a) (LPA), mRNA"},{"key":"2022092808034737400_kfac067-B9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/19420862.2017.1373924","article-title":"Capacity limits of asialoglycoprotein receptor-mediated liver targeting","volume":"9","author":"Bon","year":"2017","journal-title":"MAbs"},{"key":"2022092808034737400_kfac067-B10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/intimm\/dxt040","article-title":"Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro","volume":"26","author":"Broering","year":"2014","journal-title":"Int. Immunol"},{"key":"2022092808034737400_kfac067-B11","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J. Lipid Res"},{"key":"2022092808034737400_kfac067-B12","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"2022092808034737400_kfac067-B13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther"},{"key":"2022092808034737400_kfac067-B14","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol"},{"key":"2022092808034737400_kfac067-B15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2022092808034737400_kfac067-B16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: The promise and the challenges from a toxicologic pathologist\u2019s perspective","volume":"43","author":"Frazier","year":"2015","journal-title":"Toxicol. Pathol"},{"key":"2022092808034737400_kfac067-B17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"2022092808034737400_kfac067-B18","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"2022092808034737400_kfac067-B19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/nat.2015.0593","article-title":"Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics","volume":"26","author":"Henry","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"2022092808034737400_kfac067-B20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther"},{"key":"2022092808034737400_kfac067-B21","author":"ICH Topic S7B: Guidance for Industry: Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals","year":"2005"},{"key":"2022092808034737400_kfac067-B22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/nat.2016.0622","article-title":"Exposure to siRNA-GalNAc conjugates in systems of the standard test battery for genotoxicity","volume":"26","author":"Janas","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"2022092808034737400_kfac067-B23","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0192623318792537","article-title":"The nonclinical safety profile of GalNAc-conjugated RNAi therapeutics in subacute studies","volume":"46","author":"Janas","year":"2018","journal-title":"Toxicol. Pathol"},{"key":"2022092808034737400_kfac067-B24","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/nar\/gkz140","article-title":"Safety evaluation of 2\u2032-deoxy-2\u2032-fluoro nucleotides in GalNAc-siRNA conjugates","volume":"47","author":"Janas","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2022092808034737400_kfac067-B25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen city heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2022092808034737400_kfac067-B26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat. Med"},{"key":"2022092808034737400_kfac067-B27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/biomedicines9091271","article-title":"Modern approaches to lower lipoprotein(a) concentrations and consequences for cardiovascular diseases","volume":"9","author":"Korneva","year":"2021","journal-title":"Biomedicines"},{"key":"2022092808034737400_kfac067-B28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2018.04.032","article-title":"Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate","volume":"274","author":"Kostner","year":"2018","journal-title":"Atherosclerosis"},{"key":"2022092808034737400_kfac067-B29","doi-asserted-by":"crossref","first-page":"e1004494","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet"},{"key":"2022092808034737400_kfac067-B30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA interference-induced innate immunity, off-target effect, or immune adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol"},{"key":"2022092808034737400_kfac067-B31","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"2022092808034737400_kfac067-B32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2022092808034737400_kfac067-B33","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022092808034737400_kfac067-B34","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"2022092808034737400_kfac067-B35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","article-title":"Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease","volume":"349","author":"Rider","year":"2022","journal-title":"Atherosclerosis"},{"key":"2022092808034737400_kfac067-B36","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov"},{"key":"2022092808034737400_kfac067-B37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov"},{"key":"2022092808034737400_kfac067-B38","doi-asserted-by":"crossref","first-page":"e0187574","DOI":"10.1371\/journal.pone.0187574","article-title":"Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia","volume":"12","author":"Sewing","year":"2017","journal-title":"PLoS One"},{"key":"2022092808034737400_kfac067-B39","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1161\/ATVBAHA.112.251306","article-title":"Mechanisms of lipoprotein(a) pathogenicity: Prothrombotic, proatherosclerotic, or both?","volume":"32","author":"Spence","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"2022092808034737400_kfac067-B40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"2022092808034737400_kfac067-B41","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/cvr\/cvab100","article-title":"Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: The emerging potential of RNA interference therapeutics","volume":"118","author":"Swerdlow","year":"2022","journal-title":"Cardiovasc. Res"},{"key":"2022092808034737400_kfac067-B42","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"2022092808034737400_kfac067-B43","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: Lipoprotein(a)","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"2022092808034737400_kfac067-B44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl. J. Med"},{"key":"2022092808034737400_kfac067-B45","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfac067\/44566761\/kfac067.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/189\/2\/237\/45989737\/kfac067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/189\/2\/237\/45989737\/kfac067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T08:06:23Z","timestamp":1664352383000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/189\/2\/237\/6613944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6,23]]},"published-print":{"date-parts":[[2022,9,24]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfac067","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,6,23]]}}}